Moreno-Jimnez EP, Flor-Garca M, Terreros-Roncal J, Rbano A, Cafini F, Pallas-Bazarra N, et al
The Aggressive Shake: We mentioned it before, but it bears repeating
In spite of these limitations, the available data provide a strong rationale for further investigation of GLP-1RAs in psoriatic disease
A comprehensive review of clinical trials from 2021 highlights that once-weekly subcutaneous semaglutide (1 mg) consistently lowered HbAc by 1.5 to 1.8% over 30 to 56 weeks, outperforming other medications including sitagliptin, dulaglutide, and insulin glargine in the SUSTAIN series.33 Real-world data from 2023 further support these findings, showing an average HbA1c reduction of approximately 0.9% and a fasting blood glucose decrease of 26 mg/dL after six months of once-weekly semaglutide use.34 These results underscore semaglutides ability to offer meaningful improvements in glycemic control and metabolic health for patients with T2DM
Research indicates that individuals with diabetes often have lower levels of glutathione, which can exacerbate oxidative damage and lead to complications such as neuropathy, retinopathy, and cardiovascular diseases
